Skip to main content

FDA warns about the dangers of anti-aging blood transfusions

It turns out that injecting old people with blood from healthy youngsters might not be the answer to health rejuvenation after all. That’s according to a statement from the U.S. Food and Drug Administration (FDA), which suggests that these claims are not only most likely junk science, but that they also pose some major potential health risks.

The idea of blood being some kind of youth restorative has been enshrined in folklore for years. However, as this Digital Trends article makes clear, it has gained momentum in recent years, through controversial efforts like the plasma treatment startup Ambrosia. Plenty of people in the scientific community have dismissed this kind of thing as being pseudoscientific snake oil — but clearly, there is enough interest in it that the FDA felt the need to come forward and offer its own warning.

“The FDA has recently become aware of reports of establishments in several states that are offering infusions of plasma from young donors to purportedly treat the effects of a variety of conditions,” the press release notes. “The conditions range from normal aging and memory loss to serious diseases like dementia, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, heart disease or post-traumatic stress disorder. We have significant public health concerns about the promotion and use of plasma for these purposes. There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product.”

The FDA points out that treatments using plasma from young donors have not gone through the kind of rigorous testing that the FDA requires. It has also not been officially recognized as helping treat aging, memory loss, or various neurological diseases such as Parkinson’s. It might additionally stop patients from seeking out safe and effective treatments in favor of something unproven and risky.

“Simply put, we’re concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies,” the FDA statement continues. “Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them and are potentially harmful. There are reports of bad actors charging thousands of dollars for infusions that are unproven and not guided by evidence from adequate and well-controlled trials.”

Will this be the final word on the matter? Almost certainly not. But it’s already having some effects. Responding to the announcement, Ambrosia has officially ceased patient treatments. Until the science is sorted, that can only be a good thing.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
This AI cloned my voice using just three minutes of audio
acapela group voice cloning ad

There's a scene in Mission Impossible 3 that you might recall. In it, our hero Ethan Hunt (Tom Cruise) tackles the movie's villain, holds him at gunpoint, and forces him to read a bizarre series of sentences aloud.

"The pleasure of Busby's company is what I most enjoy," he reluctantly reads. "He put a tack on Miss Yancy's chair, and she called him a horrible boy. At the end of the month, he was flinging two kittens across the width of the room ..."

Read more
Digital Trends’ Top Tech of CES 2023 Awards
Best of CES 2023 Awards Our Top Tech from the Show Feature

Let there be no doubt: CES isn’t just alive in 2023; it’s thriving. Take one glance at the taxi gridlock outside the Las Vegas Convention Center and it’s evident that two quiet COVID years didn’t kill the world’s desire for an overcrowded in-person tech extravaganza -- they just built up a ravenous demand.

From VR to AI, eVTOLs and QD-OLED, the acronyms were flying and fresh technologies populated every corner of the show floor, and even the parking lot. So naturally, we poked, prodded, and tried on everything we could. They weren’t all revolutionary. But they didn’t have to be. We’ve watched enough waves of “game-changing” technologies that never quite arrive to know that sometimes it’s the little tweaks that really count.

Read more
Digital Trends’ Tech For Change CES 2023 Awards
Digital Trends CES 2023 Tech For Change Award Winners Feature

CES is more than just a neon-drenched show-and-tell session for the world’s biggest tech manufacturers. More and more, it’s also a place where companies showcase innovations that could truly make the world a better place — and at CES 2023, this type of tech was on full display. We saw everything from accessibility-minded PS5 controllers to pedal-powered smart desks. But of all the amazing innovations on display this year, these three impressed us the most:

Samsung's Relumino Mode
Across the globe, roughly 300 million people suffer from moderate to severe vision loss, and generally speaking, most TVs don’t take that into account. So in an effort to make television more accessible and enjoyable for those millions of people suffering from impaired vision, Samsung is adding a new picture mode to many of its new TVs.
[CES 2023] Relumino Mode: Innovation for every need | Samsung
Relumino Mode, as it’s called, works by adding a bunch of different visual filters to the picture simultaneously. Outlines of people and objects on screen are highlighted, the contrast and brightness of the overall picture are cranked up, and extra sharpness is applied to everything. The resulting video would likely look strange to people with normal vision, but for folks with low vision, it should look clearer and closer to "normal" than it otherwise would.
Excitingly, since Relumino Mode is ultimately just a clever software trick, this technology could theoretically be pushed out via a software update and installed on millions of existing Samsung TVs -- not just new and recently purchased ones.

Read more